المؤلفون: Lina Hollenbach, Julia Rogahn, Philipp le Coutre, Susann Schulze, Lars-Olof Muegge, Jan Geissler, Julia Gruen, Christian Junghanss, Sabine Felser

المصدر: Frontiers in Oncology, Vol 14 (2024)

مصطلحات موضوعية: chronic myeloid leukemia (CML), physical exercise recommendation, health-related quality of life (QOL), myeloproliferative neoplasm (MPN), physical activity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: BackgroundTyrosine kinase inhibitors (TKIs) have significantly lowered mortality of chronic myeloid leukemia (CML) patients adjusting life expectancy to that of the standard population. However, CML and its treatment with TKIs causes a high disease burden. Physical exercise (PE) could be a non-pharmacological approach to reducing these and improving quality of life.PurposeThe aim of this study was to determine the individual disease burden as well as PE preferences of CML patients and to deduce thereof specific PE recommendations.MethodsThis multicenter survey was conducted in cooperation with the LeukaNET/Leukemia-patient network including CML patients aged ≥18 years (German Registry of Clinical Trials, DRKS00023698). The severity of selected symptoms was assessed using the adapted Myeloproliferative Neoplasms Symptom Assessment Form: 0 (absent), 1–30 (mild), 31–70 (moderate), or 71–100 (severe). Information about patients’ PE needs and preferences depending on their motivation was recorded.ResultsA total of 212 questionnaires were analyzed (52% female, median age 54 years). The prevalence of moderate-to-severe symptoms was 49% for fatigue, 40% for musculoskeletal pain, and 37% for concentration problems. Other commonly reported symptoms included skin reactions (42%) and weight gain (24%). The proportion of overweight/obese patients was 52%. Half of all respondents requested more information regarding PE. Patients with CML preferred individual training (82%), located outdoors (71%), at home (47%), or in an indoor swimming pool (31%). Regarding the training frequency, sports-inactive patients preferred a frequency of 1–2 training sessions per week, whereas sports-active patients preferred 3–4 sessions per week (p

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2024.1345050/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/3ab4b096a0ff438e95f3d09087d1bca7Test

المؤلفون: Virginie Kreutzinger, Anne Pankow, Zhivana Boyadzhieva, Udo Schneider, Katharina Ziegeler, Lars Uwe Stephan, Jan Carl Kübke, Sebastian Schröder, Christian Oberender, Philipp le Coutre, Sebastian Stintzing, Ivan Jelas

المصدر: Journal of Clinical Medicine, Vol 13, Iss 4, p 1049 (2024)

مصطلحات موضوعية: autoinflammation, imaging, myelodysplastic syndrome, VEXAS syndrome, Medicine

الوصف: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently recognized systemic autoinflammatory disease caused by somatic mutations in hematopoietic progenitor cells. This case series of four patients with VEXAS syndrome and comorbid myelodysplastic syndrome (MDS) aims to describe clinical, imaging, and hematologic disease presentations as well as response to therapy. Four patients with VEXAS syndrome and MDS are described. A detailed analysis of imaging features, hemato-oncological presentation including bone marrow microscopy and clinical–rheumatological disease features and treatment outcomes is given. All patients were male; ages ranged between 64 and 81 years; all were diagnosed with MDS. CT imaging was available for three patients, all of whom exhibited pulmonary infiltrates of varying severity, resembling COVID-19 or hypersensitivity pneumonitis without traces of scarring. Bone marrow microscopy showed maturation-disordered erythropoiesis and pathognomonic vacuolation. Somatic mutation in the UBA1 codon 41 were found in all patients by next-generation sequencing. Therapy regimes included glucocorticoids, JAK1/2-inhibitors, nucleoside analogues, as well as IL-1 and IL-6 receptor antagonists. No fatalities occurred (observation period from symptom onset: 18–68 months). Given the potential underreporting of VEXAS syndrome, we highly recommend contemporary screening for UBA1 mutations in patients presenting with ambiguous signs of systemic autoinflammatory symptoms which persist over 18 months despite treatment. The emergence of cytopenia, especially macrocytic hyperchromic anemia, should prompt early testing for UBA1 mutations. Notably conspicuous, pulmonary alterations in CT imaging of patients with therapy-resistant systemic autoinflammatory symptoms should be discussed in interdisciplinary medical teams (Rheumatology, Hematology, Radiology and further specialist departments) to facilitate timely diagnosis during the clinical course of the disease.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2077-0383/13/4/1049Test; https://doaj.org/toc/2077-0383Test

الوصول الحر: https://doaj.org/article/9facf3ef4dea4d0885b4bef8d0e029aaTest

المؤلفون: Andreas Hochhaus, Andreas Burchert, Susanne Saußele, Gabriela M Baerlocher, Jiri Mayer, Tim H Brümmendorf, Paul La Rosee, Dominik Heim, Stefan W Krause, Philipp Le Coutre, Christian Fabisch, Jenny Rinke, Thoralf Lange, Alice Fabarius, Marcel Lorch, Mathias Hänel, Frank Stegelmann, Georg-Nikolaus Franke, Markus Radsak, Volker Kunzmann, Danny Himsel, Denise Kohn, Thomas Lang, Rüdiger Hehlmann, Thomas Ernst, Markus Pfirrmann

المصدر: HemaSphere, Vol 7, p e4695659 (2023)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: http://journals.lww.com/10.1097/01.HS9.0000967540.46956.59Test; https://doaj.org/toc/2572-9241Test

الوصول الحر: https://doaj.org/article/058c2d6abf82442594508bb351be8d6cTest

المؤلفون: Thomas Ernst, Philipp Le Coutre, Martina Crysandt, Tim H Brümmendorf, Georg-Nikolaus Franke, Thomas Illmer, Andreas Burchert, Fabian Lang, Susanne Saussele, Lino Lars Teichmann, Markus Radsak, Stefan Krause, Jenny Rinke, Christian Fabisch, Thomas Lang, Markus Pfirrmann, Andreas Hochhaus

المصدر: HemaSphere, Vol 7, p e34543a6 (2023)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: http://journals.lww.com/10.1097/01.HS9.0000967536.34543.a6Test; https://doaj.org/toc/2572-9241Test

الوصول الحر: https://doaj.org/article/0f3d81dfcbbb4aa0ae6d03ccea5bcb77Test

المؤلفون: Giovanni Paolo Maria Zambrotta, Sarit Assouline, Franck E. Nicolini, Elisabetta Abruzzese, Ester Pungolino, Maria Cristina Miggiano, Chiara Elena, Alberto Alvarez Larran, Ana Triguero Moreno, Alessandra Iurlo, Cristina Bucelli, Francesca Lunghi, Isabella Capodanno, Margherita Maffioli, Sara Galimberti, Giovanni Caocci, Fabio Stagno, Susanne Saussele, Carmen Fava, Philipp Le Coutre, Massimiliano Bonifacio, Veronica Guglielmana, Federica Colombo, Laura Antolinni, Carlo Gambacorti-Passerini

المصدر: HemaSphere, Vol 7, p e68411a2 (2023)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: http://journals.lww.com/10.1097/01.HS9.0000969572.68411.a2Test; https://doaj.org/toc/2572-9241Test

الوصول الحر: https://doaj.org/article/b92efaff02264a589e977952f546a4bbTest

المؤلفون: Philipp Le Coutre, Joachim Göthert, Susanne Saussele, Uwe Pelzer, Lars Bullinger, Ahmet Elmaagacli, Christian Jehn, Frank Stegelmann, Andreas Hochhaus, Thomas Ernst, Andreas Burchert

المصدر: HemaSphere, Vol 7, p e1679700 (2023)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: http://journals.lww.com/10.1097/01.HS9.0000969600.16797.00Test; https://doaj.org/toc/2572-9241Test

الوصول الحر: https://doaj.org/article/e347f84a4eb54e31831d262636c8584bTest

المؤلفون: Nina Winkelmann, Michaela Schwarz, Bert Hildebrandt, Oliver Henke, Lars Bullinger, Il‐Kang Na, Sebastian Stintzing, Philipp le Coutre

المصدر: eJHaem, Vol 3, Iss 3, Pp 949-953 (2022)

مصطلحات موضوعية: chronic myeloid leukemia, colorectal cancer, secondary malignancy, Diseases of the blood and blood-forming organs, RC633-647.5

الوصف: Abstract In this analysis, we examined the risk of secondary malignancies for tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) patients. We also collected data on specific risk factors for colorectal cancer. Ninety‐one patients with CML and 76 controls were included and in total 4 (4.4%) secondary malignancies were found in patients and 8 (10.5%) in controls. The risk for secondary malignancies was not significantly elevated for CML patients (p = 0.141). Two (2.2%) CML patients developed colorectal cancer compared to 4 (5.3%) in the reference group. A higher risk for CML patients for colorectal cancer could not be found (p = 0.414).

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2688-6146Test

الوصول الحر: https://doaj.org/article/54f065c65b1b4468aa13636b34af3f54Test

المؤلفون: Sabine Felser, Julia Rogahn, Philipp le Coutre, Haifa Kathrin Al-Ali, Susann Schulze, Lars-Olof Muegge, Julia Gruen, Jan Geissler, Veronika Kraze-Kliebhahn, Christian Junghanss

المصدر: Frontiers in Oncology, Vol 12 (2023)

مصطلحات موضوعية: anxieties, education, fatigue, fears, health-related quality of life (HrQoL), myeloproliferative neoplasms (MPN), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: BackgroundPhysical activity (PA) is a non-pharmacological approach to alleviate symptom burden and improve health-related quality of life (HrQoL) in cancer patients (pts). Whether pts with myeloproliferative neoplasms (MPN) PA behavior changes due to symptom burden and/or knowledge of the putative beneficial effects of PA has not yet been investigated.MethodsWe performed a large questionnaire study in MPN pts. Self-reported PA behavior and potential influencing factors of 634 MPN pts were analyzed. Questionnaires were used to assess demographics, anxiety, severity of symptoms, HrQoL, current level of everyday and sports activities, and the level of information regarding the importance/possibilities of PA. According to their PA, the pts were assigned to the three groups: “inactive”, “non-targeted active”, and “sporty active” and compared with each other.ResultsKey findings are that in 73% of the pts, the disease had an impact on PA, with 30% of pts reducing their PA. The prevalence of anxieties (e.g., occurrence of thrombosis and bleeding) regarding PA was 45%. Sporty active pts had a lower symptom burden and better HrQoL (p ≤ 0.001) compared to the other groups. Inactive pts were significantly older and had a higher body mass index than sporty active pts. Inactive and non-targeted active pts felt less informed about the importance/possibilities of PA (p = 0.002).ConclusionOur results suggest that especially older and non-sporty MPN pts could benefit from motivational as well as disease-specific PA information. This study was registered at the German Registry of Clinical Trials, DRKS00023698.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2022.1056786/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/0bbcbf83eaeb438eb57668f6a2729ccdTest

المؤلفون: Nadine Lackamp, Ina Wilkemeyer, Ivan Jelas, Ulrich Keller, Lars Bullinger, Sebastian Stintzing, Philipp le Coutre

المصدر: Frontiers in Oncology, Vol 11 (2021)

مصطلحات موضوعية: sperm cryopreservation, cancer, fertility preservation, assisted reproduction techniques (ART), chemotherapy, natural fertility, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Progress in oncological treatment has led to an improved long-term survival of young male cancer patients over the last decades. However, standard cancer treatments frequently implicate fertility-damaging potential. Cryopreservation of sperm is the current standard option to preserve patient’s fertility after treatment, yet long-term data on usage and reproductive experiences is still limited. Natural fertility after treatment and especially in relation to the type of treatment has been poorly analyzed so far. Therefore, we performed a retrospective survey including male patients with an indication for gonadotoxic treatment who cryopreserved reproductive material at our institution between 1994 and 2017. Study questionnaires regarding treatment, material usage, and reproductive outcomes were sent to eligible patients. Additionally, semen analyses of study participants from the time of cryopreservation were evaluated. A total of 99 patients were included in the study. Respondents’ median age was 38.0 years. Most frequent diagnoses were testicular cancer (29.3%) and lymphoma (26.3%). A further 8.1% suffered from autoimmune diseases. Testicular cancer patients had a significantly lower pre-treatment median sperm concentration (18.0 million/ml) compared to non-testicular cancer patients (54.2 million/ml). Until November 2020, the determined sperm usage and cumulative live-birth rate per couple were 17.2% and 58.8%, respectively. Most sperm users received treatments with high (40.0%) or intermediate (33.3%) gonadotoxic potential. 20.7% of all patients reported to had fathered at least one naturally conceived child after treatment, this being the case especially if they had been treated with less or potentially gonadotoxic therapies. In conclusion, our findings emphasize the importance of sperm cryopreservation in the context of male fertility preservation. Furthermore, they indicate that the gonadotoxic potential of patients’ treatments could represent a predictive factor for sperm usage.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2021.772809/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/83cf22e890bc4526981cd6064cef9428Test

المؤلفون: Elena Mylonas, Kenichi Yoshida, Mareike Frick, Kaja Hoyer, Friederike Christen, Jaspal Kaeda, Matthias Obenaus, Daniel Noerenberg, Cornelius Hennch, Willy Chan, Yotaro Ochi, Yuichi Shiraishi, Yusuke Shiozawa, Thorsten Zenz, Christopher C. Oakes, Birgit Sawitzki, Michaela Schwarz, Lars Bullinger, Philipp le Coutre, Matthew J. J. Rose-Zerilli, Seishi Ogawa, Frederik Damm

المصدر: Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)

مصطلحات موضوعية: Science

الوصف: Myelofibrosis is a myeloproliferative neoplasm. Here, the authors show the clonal evolution of myelofibrosis during JAK inhibitor therapy, revealing how the treatment results in an increase in clonal complexity and a gain of RAS pathway mutations.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2041-1723Test

الوصول الحر: https://doaj.org/article/7e23582169274e9ab60ff7109190fa37Test